Clinical trials: Diseases of the Urinary System
Chronic Renal Failure
PD-Improved Dialysis Efficiency With Adapted APD
The aim of this study is to observe the effect of adapted APD (aAPD) on maintenance and/or improvement of the hydration status of more than 250 PD patients, and to observe the tolerability of the therapy over a long period.
- Trial name
- PD-IDEA (NCT02470598)
- Testing
- Treatment with Adapted Automated Peritoneal Dialysis (aAPD)
- Where
- 50 sites in Czechia, Denmark and 4 more
- Volunteers
- 182 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Kidney Diseases, Kidney Transplant Infection
Reduction of BK Viremia in Kidney Transplant Patients
Reduction of BK Viremia by treating kidney transplant patients.
- Conditions
- Kidney Diseases, Kidney Transplant Infection, Kidney Transplant; Complications
- Trial name
- CP026 (NCT04984902)
- Testing
- Extracorporal therapy
- Where
- Germany
- Sponsor
- ExThera Medical Europe BV
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04471337
- Testing
- BAY1817080
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Hepatic Impairment; Renal Impairment
Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding
E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants.
- Trial name
- NCT02998775
- Testing
- Plasma Sampling
- Where
- 3 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Urinary Bladder Neoplasms, Urologic Neoplasms
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC).
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Trial name
- FORAY (NCT07827612)
- Testing
- Vepugratinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Eli Lilly and Company
Chronic Renal Failure
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Chronic Renal Failure
Chronic renal failure (CRF, or "chronic kidney failure", CKF, or "chronic kidney disease", CKD) is a slowly progressive loss of renal function over a period of months or years and defined as an abnormally low glomerular…
- Trial name
- NCT01152411
- Testing
- Autologous bone marrow stem cells
- Where
- India
- Volunteers
- 5 people
- Sponsor
- International Stemcell Services Limited
Chronic Kidney Diseases, Acute Kidney Injury
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone.
- Conditions
- Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
- Trial name
- NAD agent (NCT06866236)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Ebima Clifford Okundaye
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Healthy Volunteers, Renal Failure
Pharmacokinetics in End Stage Renal Disease Patients
The study is a multicentre, open label, phase I, two arms study to compare pharmacokinetic of firibastat after a single oral dose of firibastat 500 mg in fourteen healthy male volunteers and in fourteen End Stage Renal Disease…
- Trial name
- NCT04792333
- Testing
- firibastat
- Where
- France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Secondary Hyperparathyroidism, End-Stage Renal Disease
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT).
- Trial name
- NCT01134315
- Testing
- Paricalcitol, Calcitriol
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Failure
Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
- Trial name
- NCT00844662
- Testing
- Fermagate, Sevelamer hydrochloride
- Where
- 109 sites in United States, Belgium and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Ineos Healthcare Limited
Carcinoma, Renal Cell
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
This study is to assess sorafenib as second treatment for patients that have previously received only sunitinib as first-line treatment for advanced renal cell cancer, and who either responded and then progressed with sunitinib…
- Trial name
- NCT00678288
- Testing
- Sorafenib (Nexavar, BAY43-9006), Sorafenib (Nexavar, BAY43-9006) + Interferon
- Where
- 35 sites in Austria, France and 5 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Stress Urinary Incontinence
Solace Stress Urinary inContinence Control Efficacy and Safety Study
The SUCCESS Trial is designed to determine whether the Solace Bladder Control System is safe and effective for the treatment of Stress Urinary Incontinence (SUI) in adult females.
- Trial name
- SUCCESS (NCT02210273)
- Testing
- Solace Bladder Control (Vesair) Balloon
- Where
- 20 sites in United States
- Volunteers
- 221 people
- Sponsor
- Solace Therapeutics, Inc.
Hyponatremia
Study of Ascending Levels of Tolvaptan in Hyponatremia
The purpose of this study was to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal and to characterize and quantify the potential clinical benefits of this…
- Trial name
- SALT2 (NCT00201994)
- Testing
- Tolvaptan
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Metastatic Renal Cell Carcinoma
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.
- Trial name
- RECORD-1 (NCT00410124)
- Testing
- RAD001
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Chronic Renal Insufficiency
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).
- Trial name
- NCT00095056
- Testing
- sitagliptin, glipizide
- Volunteers
- 91 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Diseases
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
- Trial name
- NCT04990427
- Testing
- CLBS201
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Lisata Therapeutics, Inc.
End-Stage Renal Disease
Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.
The purpose of this study is to investigate the pharmacokinetics of donepezil HCl 3 mg in subjects with end-state renal disease who were receiving haemodialysis.
- Trial name
- NCT01063556
- Testing
- donepezil HCl
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Eisai Co., Ltd.
Urinary Bladder, Overactive
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency.
- Trial name
- NCT01302054
- Testing
- Fesoterodine 8 mg
- Where
- 176 sites in United States, Bulgaria and 13 more
- Volunteers
- 990 people
- Sponsor
- Pfizer
Stress Urinary Incontinence
Solace European Confirmatory Trial
The Solace European Confirmatory (SOLECT) Trial is designed to determine whether the Solace Bladder Control System is safe and effective for the treatment of Stress Urinary Incontinence (SUI) in adult females.
- Trial name
- SOLECT (NCT01676662)
- Testing
- Solace Bladder Control System
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 80 people
- Sponsor
- Solace Therapeutics, Inc.